Improving the prognosis for lung cancer patients

References

• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–594.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–2092.
   PubMed Web of Science ®Google Scholar
• Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175–180.
   PubMed Web of Science ®Google Scholar
• Sverzellati N, Silva M, Calareso G, et al. Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen. Eur Radiol. 2016;26:3821–3829.
   PubMed Web of Science ®Google Scholar
• Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012;21:308–315.
   PubMed Web of Science ®Google Scholar
• Zompatori M, Mascalchi M, Ciccarese F, et al. Screening for lung cancer using low-dose spiral CT: 10 years later, state of the art. Radiol Med. 2013;118:51–61.
   PubMed Web of Science ®Google Scholar
• Yousaf-Khan U, van der Aalst C, de Jong PA, et al. Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. Thorax. 2017;72:48–56.
   PubMed Web of Science ®Google Scholar
• Moyer VA. Force USPST. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160:330–338.
   PubMed Web of Science ®Google Scholar
• Ytterstad E, Moe PC, Hjalmarsen A. COPD in primary lung cancer patients: prevalence and mortality. Int J Chron Obstruct Pulmon Dis. 2016;11:625–636.
   PubMed Web of Science ®Google Scholar
• Loganathan RS, Stover DE, Shi W, et al. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest. 2006;129:1305–1312.
   PubMed Web of Science ®Google Scholar
• Amini A, Verma V, Glaser SM, et al. Early mortality of stage IV non-small cell lung cancer in the United States. Acta Oncol. 2019;8:1–7.
   Google Scholar
• Gottlieb M, Marsaa K, Godtfredsen NS, et al. Prevalence and management of pulmonary comorbidity in patients with lung and head and neck cancer. Acta Oncol. 2015;54:767–771.
   PubMed Web of Science ®Google Scholar
• Nilsson J, Berglund A, Bergström S, et al. The role of comorbidity in the management and prognosis in nonsmall cell lung cancer: a population-based study. Acta Oncol. 2017;56:949–956.
   PubMed Web of Science ®Google Scholar
• Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of non-small cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008;26:54–59.
   PubMed Web of Science ®Google Scholar
• Grønberg BH, Sundstrøm S, Kaasa S, et al. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer. 2010;46:2225–2234.
   PubMed Web of Science ®Google Scholar
• Isaksson S, George AM, Jönsson M, et al. Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence. Acta Oncol. [cited 2019 Jun 24]. DOI:10.1080/0284186X.2019.1610573
   Google Scholar
• Reiniger L, Téglási V, Pipek O, et al. Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma. Acta Oncol. 2019;19:1–8.
   Google Scholar
• Iagaru A, Gambhir SS. Imaging tumor angiogenesis: the road to clinical utility. AJR Am J Roentgenol. 2013;201:W183–91.
   PubMed Web of Science ®Google Scholar
• Skovgaard D, Persson M, Brandt-Larsen M, et al. Safety, dosimetry, and tumor detection ability of 68Ga-NOTA-AE105: first-in-human study of a novel radioligand for uPAR PET imaging. J Nucl Med. 2017;58:379–386.
   PubMed Web of Science ®Google Scholar